SARS-CoV-2 Antibodies in Children with Chronic Disease from a Pediatric Gastroenterology Outpatient Clinic

다국어 초록 (Multilingual Abstract)

Purpose: At the beginning of the Coronavirus disease (COVID-19) epidemic, physicians paid close attention to children with chronic diseases to prevent transmission or a severe course of infection. We aimed to measure the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels in children with chronic gastrointestinal and liver diseases to analyze the risk factors for infection and its interaction with their primary disease.
Methods: This cross-sectional study analyzed SARS-CoV-2 antibody levels in patients with gastrointestinal and liver diseases (n=141) and in healthy children (n=48) between January and February 2021.
Results: During the pandemic, 10 patients (7%) and 1 child (2%) had confirmed COVID-19 infection (p=0.2). The SARS-CoV-2 antibody test was positive in 36 patients (25.5%) and 11 children (22.9%) (p=0.7). SARS-CoV-2 antibody positivity was found in 20.4%, 26.6%, 33.3%, and 33.3% of patients with chronic liver diseases, chronic gastrointestinal tract diseases, cystic fibrosis, and liver transplantation recipients, respectively (p>0.05, patients vs. healthy children). Risk factors for SARS-CoV-2 antibody positivity were COVID-19-related symptoms (47.2% vs. 14.2%, p=0.00004) and close contact with SARS-CoV-2 polymerase chain reaction-positive patients (69.4% vs. 9%, p<0.00001). The use, number, and type of immunosuppressants and primary diagnosis were not associated with SARS-CoV-2 antibody positivity. The frequency of disease activation/flare was not significant in patients with (8.3%) or without (14.2%) antibody positivity (p=0.35).
Conclusion: SARS-CoV-2 antibodies in children with chronic gastrointestinal and liver diseases are similar to that in healthy children. Close follow-up is important to understand the long-term effects of past COVID-19 infection in these children.

참고문헌 (Reference)

1 Nicastro E, "The impact of severe acute respiratory syndrome coronavirus type 2 on children with liver diseases : a joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation position paper" 74 : 159-170, 2022

2 Ludvigsson JF, "Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults" 109 : 1088-1095, 2020

3 Kehar M, "Severe Acute respiratory syndrome coronavirus-2 infection in children with liver transplant and native liver disease : an international observational registry study" 72 : 807-814, 2021

4 Buescher G, "SARS-CoV-2 in pediatric liver transplant recipients : the European experience" 74 : 41-42, 2022

5 Corrias A, "Risk, course, and effect of SARS-CoV-2infection in children and adults with chronic inflammatory bowel diseases" 8 : 753-, 2021

6 Turner D, "Paediatric IBD Porto group of ESPGHAN. Corona virus disease 2019 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition" 70 : 727-733, 2020

7 Cakir M, "New-onset celiac disease in children during COVID-19 pandemic" 111 : 383-388, 2022

8 Tannuri U, "Low incidence of COVID-19 in children and adolescent post-liver transplant at a Latin American reference center" 75 : e1986-, 2020

9 Romanelli A, "Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019 : a therapeutical hypothesis" 20 : 1947-1948, 2020

10 Cheung KS, "Gastrointestinal manifestations of SARSCoV-2 infection and virus load in fecal samples from a Hong Kong cohort : systematic review and metaanalysis" 159 : 81-95, 2020

11 Akobeng AK, "Gastrointestinal manifestations of COVID-19 in children : a systematic review and meta-analysis" 12 : 332-337, 2020

12 Tullie L, "Gastrointestinal features in children with COVID-19 : an observation of varied presentation in eight children" 4 : e19-20, 2020

13 Assa A, "Gastrointestinal Committee of ESPGHAN. Gastrointestinal perspective of coronavirus disease 2019 in children-an updated review" 73 : 299-305, 2021

14 Colmenero J, "Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients" 74 : 148-155, 2021

15 Roche Diagnostics GmbH, "Elecsys® Anti-SARS-CoV-2 S assay" Roche Diagnostics GmbH

16 Sansotta N, "Children with inflammatory bowel disease in the COVID-19 main endemic focus : the Lombardy experience" 9 : 607285-, 2021

17 Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention" 323 : 1239-1242, 2020

18 Di Giorgio A, "COVID-19 in children with liver disease" 9 : 2021

19 Marjot T, "COVID-19 and liver disease : mechanistic and clinical perspectives" 18 : 348-364, 2021

20 Sin P, "Acute liver injury among pediatric liver transplantation recipients with coronavirus disease 2019: an international collaborative study" 74 : 391-394, 2022

21 Yuksel M, "A single-center report of COVID-19 disease course and management in liver transplanted pediatric patients" 25 : e14061-, 2021

22 Di Giorgio A, ""Health status of children with chronic liver disease during the SARS-CoV-2 outbreak : results from a multicentre study"" 45 : 101610-, 2021